

SUBJECT INDEX TO VOLUME 6

Acute myeloid leukemia (AML)	543	Amplicon-6 vector	408
molecular basis of	543	construction of	408
targeting Ras signaling in	545	Angiogenesis	612
Adeno-associated virus	315,683	human gene therapy trials of	612
hematopoietic stem cell gene transfer by	689	Antisense DNA	131
interactions/interference between		Antisense RNA	133
HSV-1/AAV	319	Apoptosis	19
intracellular trafficking of	685	Arthritis	256
mediated gene transfer in hematopoietic		systemic delivery of cytokine inhibitors in	256
stem	683	Autoimmunity	46
obstacles to	684	development of	46
second-strand DNA synthesis	687	thymic tolerance in	46
uncoating of	686	Autologous hematopoietic stem cell transplants	50
Adenosine deaminase	692	Bacterial artificial chromosomes	326
deficiency of	692	as gateway to genome	326
Adenoviral vector	215	in gene therapy	327
cell surface receptor interactions with	219	non-viral delivery of genomic loci as	327
future directions for	215	reporter gene studies of	327
immunity by	214	Bone morphogenetic proteins	553
in immunomodulation	218	in tooth development	553
in immunosuppression	218	in tooth regeneration	553
induction of innate immune response by	216	Brattleboro rat	125
strategies for	215	Breast cancer stem cells	584
toxicity by	216	C31 integrase	633
Allogeneic hematopoietic stem cell transplants	50	advantages/disadvantages of	640
Amplicons	383	gene therapy studies with	636
as vaccine vectors	383	improvements to	641
effect of pre-existing immunity on		integration sites of	634
vaccines based on	387	mode of action in mammalian cells	633
interaction with DC/APC	384	non-gene therapy uses of	636
use for cancer vaccination/immunotherapy	385	safety of	639
use for immunization against microbial		Cancer	112,361,505,579
pathogens	386	differentiation therapy of	581
use for immuno-prevention or immunotherapy		HSV amplicon vectors for therapy of	361
of neurologic disease	387	HSV/AAV (or EBV)RV tribrid amplicon for	
Amplicon vectors	351,361,408	therapy of.....	362
anti-angiogenic therapy by	363	HSV/AAV hybrid amplicons for therapy of ...	361
bioluminescence imaging (BLI) of	367	HSV/EBV hybrids for therapy of.....	362
immunotherapy by	363	hybrid amplicon vectors for therapy of	361
in addiction	353	role of ataxia telangiectasia mutated protein	
in anxiety	353	(ATM)	114
in behavior	352	role of BRCA1	116
in learning/memory	354	role of DNA double-strand break repair	112
in social interaction	353	role of HRR pathway	112
in stress	353	role of MRN complex	118
magnetic resonance imaging (MRI)	367	role of NHEJ pathway	112
near-infrared fluorescence (NIRF) imaging of	367	role of RAD51	117
PET imaging of	365	targeting DNA repair proteins for	114
prodrug activation by	364		
to study/modify cognitive functions	351		
with siRNA	365		
Amplicon vector plasmids	307		
flexible design of	307		

therapeutic delivery in	362	amplicon vectors	303
stem cells origin of	579	in versatile design of amplicon vector	
tissue invasion/metastasis in	516	plasmids	303
treating with gene silencing agents	519	for hybrid amplicon vectors	308
Cancer gene therapy	17,73,181	for regulatable amplicon vectors	309
identification of receptors for	75	DNA electrotransfer	563
immuno-isolation in	181	in cancer	572
in apoptosis	23	in immune system-related diseases	571
in cell proliferation	23	in metabolic disorders	571
in tumorigenesis	21	in monogenic diseases	568
inhibition of NF- κ B pathway in	20	in muscle diseases	568
MDA-7IL-24-based	73	in organ/tissue/specific diseases	569
modification of prodrug in	182	<i>in vivo</i> skeletal muscle based	564
role of AP-1 family	20	mechanism of	563
role of NF- κ B/REL family	18	plasmid biodistribution in	567
targeting transcription factors for	17	risk of integration in	567
vaccine delivery for	184	safety considerations of	565
Cardiovascular disease	609	toxicity of	565
cell therapy for	613,616	DNA repair	485
gene therapy for	609,610	AAV vector-mediated	491
stem cells for	614	assays in animal models for	486
Cell survival	19	mammalian cell-based systems for	485
Chloroquine	473	modified single-stranded oligonucleotides for	488
Chronic granulomatous disease (CGD)	692	oligonucleotide-mediated	486
Ciliary neurotrophic factor (CNTF)	147	role of chimeraplasty	487
biology of	149	small fragment homologous replacement for ..	490
for Huntington's disease	147	triplex-forming oligonucleotides for	489
for retinitis pigmentosa	147	use of selectable markers for	486
human trials of	153	DNA repair proteins	111
intracompartmental delivery of	147	for cancer gene therapy	111
neuroprotection based on delivery		DNA vaccines	258
of striatum	150	against carcinoembryonic antigen (CEA)	259
Cystic fibrosis (CF)	161	against her-2/neu	258
adeno-associated virus vectors for	169	against tumors	259
approaches to enhancing gene transfer for	167	for type 1 diabetes	259
gene therapy for	163	in overcoming tumor resistance to immunity ..	258
lentiviral vectors for	171	in type 1/2	260
vectors for gene therapy of	168	induction of regulatory T cells (Tr) in	
Cytokine inhibitors	256	NOD mice by	260
in autoimmune diseases	256	Ectopic expression	52
Cytoplasmic movement	671	in experimental autoimmune diseases	52
mechanisms of	671	in induction of immunological tolerance	52
Defective viruses	277	of autoantigen in bone marrow derived cells	52
naturally occurring	277	Electroporation	243,561
Dentin regeneration	551	as tool	573
gene therapy for	551	enhancement of DNA vaccines by	257
with bone morphogenetic proteins	551	equipment for	247
Diabetic retinopathy	194	expression cassette for	245
health economics of	205	in cancer	572
pathophysiology of	194	in eye	251
DNA-based methods	303	in immune system-related diseases	571
to prepare helper virus-free herpes		in metabolic disorders	571
		in monogenic diseases	568
		in muscle diseases	568
		in organ/tissue/specific diseases	569
		in skin	250

in tumors	250	accessibility of corrective molecules for	482
<i>in vivo</i>	244	advantages of adenoviral vectors for	215
methods of	247	amplicons in	331
parameters for	247	bacteriophage Φ C31 system for	594
permeabilization in	562	barriers to	671
plasmid biodistribution in	567	basic/clinical aspects of	193
principle/mechanism of	244,562	C31 integrase system for	633
risk of integration in	567	cellular targets for gene therapy of	163
role of plasmids	244	cytoprotective genes in	451
safety considerations of	565	delivery of	586
therapeutic uses of	255	effect of disruption of airway barriers	
toxicity of	565	to vector transduction	167
uptake of DNA in	563	effect of host defenses in airway	166
Electroporation-enhanced nonviral gene transfer	243	effect on immune tolerance	45
for endocrine diseases	243	for acute myeloid leukemia	583
for neoplastic diseases	243	for acute promyelocytic leukemia	582
for prevention or treatment of immunological		for cancer stem cells	579
diseases	243	for chronic myeloid leukemia	582
plasmid constructs for	244	for cystic fibrosis airway disease	161
Encapsulated cells	147	for retinopathy induced by diabetes	193
immunoisolation from	147	genes targeting inflammatory/immune	
implant tolerability from	147	responses in	447
long term protein delivery from	147	genomic DNA vs cDNA cassettes in	326
Fanconi anemia (FA)	693	in lung transplantation	439
Gateway TM /creator TM -compatible amplicon vectors ...	309	intracellular trafficking of plasmids for	671
Gene delivery	554,611	lentiviral vectors for	536
for dentin/pulp regeneration	555	mutant leptin receptor rat models in	126
for pulse generation disorders/arrhythmias	612	NLS DNA conjugates for	677
for treatment of heart failure	612	non-viral approaches of	49
for treatment of hypertension	612	non-viral vectors for	203,673
vectors for	611	nuclear envelope as barrier for	674
Gene delivery vector	1	of lupus with cytokine inhibitors	255
alpha-herpes virus vectors as	1	potentials/challenges of	194
beta-herpes virus vectors as	2	promoters of heat shock protein genes in	423
gamma-herpes virus vectors as	2	radiation-induced promoters in	422
herpesviruses as	1	regulatable gene expression systems for	421
<i>in vitro</i> analysis of	3	regulation of therapeutic gene by	200
Gene silencing	246,505	role of cytoplasmic diffusion	671
antisense oligonucleotides in	516	role of mitosis/nuclear pore	675
as therapeutic agents	516	significance of vector immunity in	215
cellular pathways in	507	synthetic/natural polycations for	59
delivery systems in	505	target genes in	447
evasion of programmed cell death in	515	targeted gene repair by	481
in development of personalized cancer		to promote wound healing	261
treatment	505	to treat autoimmune diseases	45,47
insensitivity to growth inhibitory signals in	515	transgenic animals in	535
ribozymes in	517	viral vectors for	202,672
RNA interference in	518	Gene-directed enzyme prodrug therapy (GDEPT) ...	647
siRNA in	246	adeno-associated virus for	651
sustained angiogenesis in	516	adenovirus for	649
targets for	505	herpes simplex virus for	655
Gene therapy	45,59,125,161,193,215,255,326,421,	non-replicating vectors for	649
.....	439,481,535,579,593,633,671	replicating RNA viruses for	661
		replicating viral vectors for	654
		replication-competent retroviruses for	661
		replication-selective adenoviruses for	658
		retroviruses for	652
		Sindbis virus for	654
		thymidine kinase for	651
		vaccinia virus for	654

Genomic loci	325,328	HSV amplicon	277,337
infectious delivery of	328	alterations in viral replication patterns of	279
transgene expression from	325	as vectors for transgene expression	292
Glycosaminoglycans	35	based immunotherapy for Alzheimer's disease	346
in virus storage/protection	38	based immunotherapy for Prion disorders	342
Helper virus DNA	287	CIS acting functions for	285
deleted sequence was repaired by		class I defective genomes of	280
recombination with	287	class II defective virus genomes of	280
Helper virus-free packaging system	304	effect of cleavage-packaging signal	289
Hematopoietic stem cells	692	HSV-1 (justin) class I defective genomes of ...	278
application of AAV vectors in gene		in neuroplasticity	339
therapy involving	692	in neuroprotection	338
Hematopoietic stem cell transplantation	49	mediated neuroprotection for ototoxicity	338
immunological tolerance in	49	mediated neuroprotection for ischemic injuries	339
Hematopoietic stem/progenitor cell-specific		neuro applications of	337
promoters	690	structure of standard DNA of	278
evolution of	691	transfection of	283
use of	690	UC-DR1-UB cleavage packaging signals for .	290
Hemoglobinopathies	332,693	HSV/AAV hybrid amplicons	321
Hemophila	262	design of	321
factor VIII/IX therapy in	262	HSV/AAV hybrid vectors	376
Heparan sulphate proteoglycans	35	for cell therapy of muscle diseases	376
and protein/peptide vectors	41	HSV-1 amplicons	325,329
in gene delivery	39	delivery of large genomic DNA inserts>	
role in viral infection	36	100 kb using	325
Herpesvirus	291	for genomic locus delivery	329
conserved PAC-1/PAC-2 signals by	291	HSV-1 amplicon vectors	371
Herpesvirus Saimiri	1	as a gene delivery	374
applications of vectors of	10	as gene transfer system for skeletal	
based gene delivery vectors	1	muscle cells	371
engineering of vectors of	8	mediated <i>in vivo</i> muscle gene transfer	372
<i>in vitro</i> analysis of	3	mediated stable gene transduction for	
mechanism episomal maintenance of	7	autologous myoblast transplantation	375
HHV-6	399	HSV-1 based amplicon vectors	393
activation of	400	as system for expression of functional	
cell growth requirements of	403	HCV proteins	393
cell tropism of	402	expression of HCV structure proteins core	
cleavage/packaging of genomes	407	E1/E2 using	393
history of isolation of	399	in vaccinations	396
infectivity/disease with	400	of non-structural region	395
structure of	403	HSV-1 DNA	288
HHV-7	399	effect of cleavage-packaging signal	289
activation of	400	replication origins of	288
cell growth requirements of	403	HSV-1 infection	383
cell tropism of	402	immune responses to	383
cleavage/packaging of genomes	407	interaction with dendritic cells	384
history of isolation of	399	HSV-1/AAV hybrid amplicons	318
in disease involvement	402	applications of	318
infectivity/disease with	400	design of	318
structure of	403	limitations of	318
		HSV-2	288
		OR12 DNA replication origin of	288
		Huntington's disease (HD).....	149
		criteria for neuroprotective therapies in	150
		pathology of	149

